# \[e-drug\] Use of ceftriaxone in poor countries (6)

**URL:** <https://talk.edrugplus.org/t/e-drug-use-of-ceftriaxone-in-poor-countries-6/31096>\
**Category:** e-drug\
**Created:** [January 9, 2009, 4:12pm UTC](https://talk.edrugplus.org/t/e-drug-use-of-ceftriaxone-in-poor-countries-6/31096 "2009-01-09T16:12:40Z")\
**Posts on this page:** 1\
**Page:** 1

<div class="post-metadata">

**Author:** ![Shazia\_Jamshed](https://avatars.discourse-cdn.com/v4/letter/s/8e8cbc/32.png) [@Shazia\_Jamshed](https://talk.edrugplus.org/u/Shazia_Jamshed)\
**Post date:** [January 9, 2009, 4:12pm UTC](https://talk.edrugplus.org/t/e-drug-use-of-ceftriaxone-in-poor-countries-6/31096/1 "2009-01-09T16:12:40Z")

</div>

E-DRUG: Use of ceftriaxone in poor countries (6)  
-------------------------------------------

Dear All,

I agree with Christian as we all know that quality is the issue in generic counterparts of some therapeutic classes.

Sales of Roche's world leading injectable antibiotic Ceftriaxone exceeded US$1 billion in 2003 and 2004; faced with generic competition in 2005, sales of the branded product declined US$746 million. Lupin was first to achieve FDA ANDA approval for its generic version of ceftriaxone, followed by Sandoz, Orchid and Baxter.

A couple of studies showing differences in response to originator and generic copies:

Lambert PA and Conway BR. Pharmaceutical quality of ceftriaxone generic drug products compared with Rocephin. J Chemother 2003 Aug;15(4):357-68

Schito GC, Keenan MH. Predicting the clinical efficacy of generic formulations of ceftriaxone. J Chemother. 2005 Sep;17 Suppl 2:33-40

Shazia Jamshed  
PhD Scholar  
Social and Administrative Pharmacy  
School of Pharmaceutical Sciences  
Universiti Sains Malaysia  
Penang  
Malaysia  
Core Member Medicine Pakistan International  
E-mail: shazia\_12@yahoo.com  
[http://medicinespakistan.org/projects/](http://medicinespakistan.org/projects/)